[Interleukin-1 receptor antagonist: a new therapeutic agent in the treatment of sepsis syndrome].
Boermeester
M A
MA
Academisch Ziekenhuis Vrije Universiteit, afd. Heelkunde, Amsterdam.
van Leeuwen
P A
PA
Schneider
A J
AJ
Houdijk
A P
AP
Ferwerda
C C
CC
Wesdorp
R I
RI
D000209:Acute-Phase Proteins / Q000378:metabolism; D000818:Animals; D002352:Carrier Proteins / Q000378:metabolism; D016207:Cytokines / Q000096:biosynthesis; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D008562:Membrane Glycoproteins; D010215:Papio; D011994:Recombinant Proteins / Q000627:therapeutic use; D018805:Sepsis / Q000378:metabolism / Q000628:therapy*; D012772:Shock, Septic / Q000628:therapy; D012795:Sialoglycoproteins / Q000627:therapeutic use*; D000099231:Lipopolysaccharide-Binding Protein
D000209:Acute-Phase Proteins; D002352:Carrier Proteins; D016207:Cytokines; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D008562:Membrane Glycoproteins; D011994:Recombinant Proteins; D012795:Sialoglycoproteins; D000099231:Lipopolysaccharide-Binding Protein; C507763:IL1RN protein, human
Interleukine-1-receptorantagonist: een nieuw therapeuticum bij de behandeling van het sepsissyndroom.